Read by QxMD icon Read


Marc Humbert, Camille Taillé, Laurence Mala, Vincent Le Gros, Jocelyne Just, Mathieu Molimard
Omalizumab is a monoclonal anti-immunoglobulin E antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count (EOS) as a predictive measure for response to omalizumab. This retrospective real-life study was conducted in France between December 2015 and September 2016 using medical records of SAA omalizumab-treated patients. Response to omalizumab was assessed by three criteria: physician evaluation, reduction of ≥40% in annual exacerbation rate, and combination of both...
March 15, 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
G Authried, S C Prasad, E Rye Rasmussen, A Bygum
A subset of patients with angioedema (AE) and urticaria has histamine releasing autoanti-boies. The histamine release test (HR-test) has been used as a tool in chronic urticaria to de-fine the autoimmune subgroup and may possibly guide the clinician to a more personalized therapy, like omalizumab and cyclosporine. The prevalence and value of positive histamine releasing autoantibodies in monosymptomatic AE is sparsely described in the literature. The purpose of this study was to report the prevalence of positive histamine releasing autoanti-bodies in a cohort of patients with recurrent AE and evaluate the usefulness of this test in AE patients...
February 19, 2018: European Annals of Allergy and Clinical Immunology
Shekhar Neema, Manas Chatterjee
Aim: To study the effects of omalizumab in chronic spontaneous urticaria in Indian patients. Setting and Design: The study was conducted in a tertiary care centre and it was retrospective and descriptive in nature. Material and Methods: We analysed the data of patients who were administered omalizumab between June 2014 and June 2015 for the management of refractory chronic spontaneous urticaria at our centre. Omalizumab was used in those patients who did not respond to updosing of antihistaminics and cyclosporine...
January 2018: Indian Journal of Dermatology
Kiran Godse, Abhishek De, Vijay Zawar, Bela Shah, Mukesh Girdhar, Murlidhar Rajagopalan, D S Krupashankar
This article is developed by the Skin Allergy Research Society of India for an updated evidence-based consensus statement for the management of urticaria, with a special reference to the Indian context. This guideline includes updated definition, causes, classification, and management of urticaria. Urticaria has a profound impact on the quality of life and causes immense distress to patients, necessitating effective treatment. One approach to manage urticaria is by identification and elimination of the underlying cause(s) and/or eliciting trigger(s) while the second one is by treatment for providing symptomatic relief...
January 2018: Indian Journal of Dermatology
Antonio Sahuquillo-Torralba, Mercedes Rodríguez-Serna, Rafael Botella Estrada
No abstract text is available yet for this article.
March 8, 2018: Medicina Clínica
Gustavo Deza, Marta Bertolín-Colilla, Silvia Sánchez, Dulce Soto, Ramon M Pujol, Ramon Gimeno, Ana M Giménez-Arnau
This study suggests that baseline levels of basophil FcεRI receptor may predict time to response to anti-IgE therapy in chronic spontaneous urticaria.
March 5, 2018: Journal of Allergy and Clinical Immunology
Katharine C Pike, Melika Akhbari, Dylan Kneale, Katherine M Harris
BACKGROUND: Asthma exacerbations in school-aged children peak in autumn, shortly after children return to school following the summer holiday. This might reflect a combination of risk factors, including poor treatment adherence, increased allergen and viral exposure, and altered immune tolerance. Since this peak is predictable, interventions targeting modifiable risk factors might reduce exacerbation-associated morbidity and strain upon health resources. The peak occurs in September in the Northern Hemisphere and in February in the Southern Hemisphere...
March 8, 2018: Cochrane Database of Systematic Reviews
Eustachio Nettis, Luca Cegolon, Elisabetta Di Leo, Walter Giorgio Canonica, Aikaterini Detoraki
BACKGROUND: Omalizumab therapy is effective and safe in patients with chronic spontaneous urticaria (CSU) resistant to nonsedating histamine1 (H1 ) antihistamines (nsAHs). OBJECTIVE: To evaluate the efficacy and safety of omalizumab in elderly (aged ≥65 years) patients with nonsedating H1 -antihistamine-refractory CSU in a real-life setting. METHODS: Patients with nonsedating H1 -antihistamine-refractory CSU (n = 322) treated with omalizumab administered every 4 weeks in doses of 300 mg for 24 weeks were divided into 2 groups according to age at omalizumab treatment onset: 15 to 64 years and 65 years or older...
March 2018: Annals of Allergy, Asthma & Immunology
Anna Sztafińska, Joanna Jerzyńska, Włodzimierz Stelmach, Katarzyna Woicka-Kolejwa, Iwona Stelmach
Introduction: Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with severe persistent allergic asthma. Aim: To demonstrate the quality of life in children with severe asthma and their caregivers, and changes from baseline in forced expiratory volume in 1 s (FEV1 ) and daily inhaled corticosteroids (ICS) dose after 2-year treatment with omalizumab...
October 2017: Postȩpy Dermatologii i Alergologii
C Cavaliere, E Begvarfaj, F Frati, S Masieri
Omalizumab, a monoclonal antibody against IgE, may be effective on nasal polyps, but its use is not currently authorized to treat that disease. We report the cases of three patients who were given omalizumab for asthma after undergoing nasal surgical polypectomy. Although such procedure is frequently followed by polyp recurrence, none of the three patients developed this complication, and in one subject the regression of initial polyp return was registered after starting omalizumab. Our data support the hypothesis that omalizumab may be useful to treat nasal polyposis...
January 2018: Journal of Biological Regulators and Homeostatic Agents
J Marcelino, A C Costa, A Mendes, E Alonso, F Cabral Duarte, E Pedro, M Pereira-Barbosa
Objective. Describe the safety and long-term use of omalizumab in chronic urticaria (CU), both spontaneous (CSU) and inducible (CIndU). Methods. Retrospective chart-review (2006-15) of CU patients treated with omalizumab for ≥ 6 months. Statistical analyses: descriptive statistics, Mann-Whitney, generalized linear models. Results. 23 patients with CSU (3 men), 3 with CIndU (2 men). Generalized linear models showed UAS reduction per omalizumab administration of 16% in CIndU and CSU and UAS7, of 15% in CIndU, and 20% in CSU...
January 16, 2018: European Annals of Allergy and Clinical Immunology
T A Kanters, H B Thio, L Hakkaart
BACKGROUND: Chronic spontaneous urticaria (CSU) is a skin disease, with itchy hives and / or angioedema that last for at least 6 weeks without an obvious external trigger. OBJECTIVES: The objective of this study was to determine the cost-effectiveness of omalizumab relative to standard of care (SoC; up to 4 times the daily dose of H1-antihistaminics) for the Netherlands from a societal perspective. METHODS: The Markov model used consisted of five health states based on Urticaria Activity Score over seven days (UAS7)...
February 24, 2018: British Journal of Dermatology
Virginia Mirra, Silvia Montella, Francesca Santamaria
BACKGROUND: The primary goal of asthma management is to achieve disease control for reducing the risk of future exacerbations and progressive loss of lung function. Asthma not responding to treatment may result in significant morbidity. In many children with uncontrolled symptoms, the diagnosis of asthma may be wrong or adherence to treatment may be poor. It is then crucial to distinguish these cases from the truly "severe therapy-resistant" asthmatics by a proper filtering process...
February 21, 2018: BMC Pediatrics
(no author information available yet)
BACKGROUND: Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014. OBJECTIVE: This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients withCIU/CSU. METHODS: Patients with CIU/CSU (ages greater than or equal to 12 years) initiated on omalizumab (index date) with greater than or equal to 12 months of pre- and postindex data were identified in the an insurance claims data base (January 1, 2013, to July 31, 2016)...
February 19, 2018: Allergy and Asthma Proceedings:
J D M Hughes, T Olynyc, H Chapdelaine, L Segal, B Miedzybrodzki, M Ben-Shoshan
Omalizumab (Xolair ® ) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.
February 16, 2018: Clinical and Experimental Dermatology
B Murphy, M Duffin, J Tolland
No abstract text is available yet for this article.
February 16, 2018: Clinical and Experimental Dermatology
Kevin L Winthrop, Xavier Mariette, Jose T Silva, Esther Benamu, Leonard H Calabrese, Alexandre Dumusc, Josef S Smolen, José María Aguado, Mario Fernández-Ruiz
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
February 12, 2018: Clinical Microbiology and Infection
Corinna Dressler, Ricardo Niklas Werner, Lisa Eisert, Torsten Zuberbier, Alexander Nast, Marcus Maurer
BACKGROUND: Chronic inducible urticaria (CindU) is a condition characterized by the appearance of recurrent wheals, angioedema or both, as a response to specific and reproducible triggers. OBJECTIVE: To systematically assess the evidence on the efficacy and safety of treatment options for CindU. Results were used to inform the 2017 update of "The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria." METHODS: Randomised controlled trials (RCTs) and controlled studies (CCTs) were systematically searched in various databases...
February 10, 2018: Journal of Allergy and Clinical Immunology
Jonathan A Bernstein, Abhishek Kavati, Michael D Tharp, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck, Ivo Abraham
Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological condition characterized by itchy wheals and/or angioedema of continuous or intermittent duration of ≥6 weeks with a high burden of disease and impact on quality of life. Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of IgE to high affinity receptors, and is approved for the CIU/CSU indication. The objective of this systematic review was to evaluate and synthesize the evidence on the real-world effectiveness of omalizumab in CIU/CSU in daily clinical practice...
February 12, 2018: Expert Opinion on Biological Therapy
William C Anderson, Stanley J Szefler
Strategies to control the risk domain of NHLBI EPR-3 (National Heart, Lung, and Blood Institute Expert Panel Report-3) asthma guidelines, which includes exacerbations requiring systemic corticosteroids, reduction in lung growth, and progressive loss of lung function, and treatment-related adverse effects, are evolving in children and adolescents. Increasing evidence demonstrates that children and adolescents with asthma are at risk of a reduction in lung growth, leading to lower lung function and potentially chronic obstructive pulmonary disease as adults...
February 2018: Seminars in Respiratory and Critical Care Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"